Galectin Therapeutics (GALT) Competitors $1.25 0.00 (0.00%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$1.27 +0.02 (+1.92%) As of 01/31/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GALT vs. ENGN, TRVI, SOPH, ATYR, DSGN, CTNM, YMAB, IMMP, ELDN, and ITOSShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include enGene (ENGN), Trevi Therapeutics (TRVI), SOPHiA GENETICS (SOPH), Atyr PHARMA (ATYR), Design Therapeutics (DSGN), Contineum Therapeutics (CTNM), Y-mAbs Therapeutics (YMAB), Immutep (IMMP), Eledon Pharmaceuticals (ELDN), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry. Galectin Therapeutics vs. enGene Trevi Therapeutics SOPHiA GENETICS Atyr PHARMA Design Therapeutics Contineum Therapeutics Y-mAbs Therapeutics Immutep Eledon Pharmaceuticals iTeos Therapeutics Galectin Therapeutics (NASDAQ:GALT) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk. Do institutionals & insiders hold more shares of GALT or ENGN? 11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 50.1% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 13.7% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is GALT or ENGN more profitable? Galectin Therapeutics' return on equity of 0.00% beat enGene's return on equity.Company Net Margins Return on Equity Return on Assets Galectin TherapeuticsN/A N/A -163.15% enGene N/A -16.69%-14.27% Do analysts prefer GALT or ENGN? Galectin Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 780.00%. enGene has a consensus price target of $29.78, indicating a potential upside of 344.44%. Given Galectin Therapeutics' higher possible upside, equities analysts plainly believe Galectin Therapeutics is more favorable than enGene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00enGene 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Does the media refer more to GALT or ENGN? In the previous week, enGene had 3 more articles in the media than Galectin Therapeutics. MarketBeat recorded 6 mentions for enGene and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.76 beat enGene's score of 0.66 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, GALT or ENGN? Galectin Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.65, suggesting that its stock price is 165% less volatile than the S&P 500. Does the MarketBeat Community believe in GALT or ENGN? Galectin Therapeutics received 331 more outperform votes than enGene when rated by MarketBeat users. However, 100.00% of users gave enGene an outperform vote while only 59.11% of users gave Galectin Therapeutics an outperform vote. CompanyUnderperformOutperformGalectin TherapeuticsOutperform Votes34759.11% Underperform Votes24040.89% enGeneOutperform Votes16100.00% Underperform VotesNo Votes Which has higher valuation and earnings, GALT or ENGN? enGene is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectin TherapeuticsN/AN/A-$41.07M-$0.73-1.71enGeneN/AN/A-$55.14M-$0.58-11.55 SummaryGalectin Therapeutics and enGene tied by winning 8 of the 16 factors compared between the two stocks. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.45M$6.86B$5.58B$9.11BDividend YieldN/A2.90%5.31%3.99%P/E Ratio-1.719.4588.1918.21Price / SalesN/A320.211,259.7183.20Price / CashN/A73.5045.9637.70Price / Book-1.245.275.124.70Net Income-$41.07M$136.98M$111.40M$224.47M7 Day Performance2.46%-0.73%2.33%-0.20%1 Month Performance-3.10%0.16%3.19%0.57%1 Year Performance-28.16%7.59%24.62%20.30% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics1.5274 of 5 stars$1.25flat$11.00+780.0%-26.0%$78.45MN/A-1.719Positive NewsENGNenGene3.052 of 5 stars$6.83-4.7%$29.78+336.3%-14.5%$303.79MN/A-11.8431Short Interest ↓News CoverageTRVITrevi Therapeutics2.5838 of 5 stars$3.87-1.2%$9.31+140.9%+177.5%$297.10MN/A-8.7820Short Interest ↓News CoverageSOPHSOPHiA GENETICS2.8195 of 5 stars$4.44+5.6%$7.40+66.9%-23.7%$289.94M$64.49M-4.07520Short Interest ↓Gap DownHigh Trading VolumeATYRAtyr PHARMA2.4713 of 5 stars$3.44-4.3%$19.25+460.4%N/A$287.49M$350,000.00-3.6453Short Interest ↑News CoveragePositive NewsDSGNDesign Therapeutics2.1546 of 5 stars$5.00+0.6%$7.00+40.0%+104.6%$282.26MN/A-5.8640Short Interest ↑News CoverageGap DownCTNMContineum Therapeutics3.2561 of 5 stars$10.93-2.2%$29.25+167.6%N/A$281.78M$50M0.0031Upcoming EarningsYMABY-mAbs Therapeutics2.128 of 5 stars$6.24-0.2%$20.89+234.9%-53.3%$279.36M$84.82M-11.55150IMMPImmutep1.8904 of 5 stars$1.92-2.5%$8.50+343.9%-3.7%$278.75M$5.14M0.002,021News CoverageELDNEledon Pharmaceuticals3.0962 of 5 stars$4.60+3.8%$16.00+247.8%+153.9%$274.80MN/A-2.2910Analyst ForecastShort Interest ↓Positive NewsITOSiTeos Therapeutics4.117 of 5 stars$7.52-1.6%$22.25+195.9%-24.2%$274.71M$12.60M-2.3990Short Interest ↓ Related Companies and Tools Related Companies ENGN Alternatives TRVI Alternatives SOPH Alternatives ATYR Alternatives DSGN Alternatives CTNM Alternatives YMAB Alternatives IMMP Alternatives ELDN Alternatives ITOS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GALT) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredThe #1 Stock for Trump’s First 100 DaysLegendary investor Louis Navellier believes this is just the beginning of Trump's 100-day melt-up. You shou...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GALT Stock Alerts